Vaxart Inc. PT receives Investment Bank Analyst Rating Update
Investing.com - Vaxart reported on Tuesday third quarter earnings that beat analysts' forecasts and revenue that fell short of expectations. Vaxart announced earnings per share...
By Peter Nurse Investing.com -- Stocks in focus in premarket trade on Tuesday, May 4th. Please refresh for updates. Pfizer (NYSE:PFE) stock rose 0.9% after the drugmaker...
Vaxart, Inc. is a clinical-stage biotechnology company that is primarily focused on the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology (VAAST) oral vaccine platform. Its programs include tablet vaccines designed to protect against coronavirus, norovirus, seasonal influenza and respiratory syncytial virus (RSV), as well as a therapeutic vaccine for human papillomavirus (HPV). The Company’s product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; influenza vaccine, which is in Phase II clinical trial for the treatment of H1 influenza infection; respiratory syncytial virus vaccine; and coronavirus vaccine, which is in Phase II clinical trial for the treatment of SARS-CoV-2 infection. The Company is also developing therapeutic vaccines for cervical cancer and dysplasia caused by human papillomavirus.